1 Designs for Oncology MTD Finding Yevgen Tymofyeyev MERCK & Co., Inc September 12, 2008.
1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research...
-
Upload
kristian-neal-bell -
Category
Documents
-
view
217 -
download
0
Transcript of 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research...
![Page 1: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/1.jpg)
1
Keaven Anderson, Ph.D.
Amy Ko, MPH
Nancy Liu, Ph.D.
Yevgen Tymofyeyev, Ph.D.
Merck Research Laboratories
June 9, 2010June 9, 2010
Information-Based Sample SizeRe-estimation for Binomial Trials
![Page 2: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/2.jpg)
2
Objective: Fit-for-purpose sample-size adaptation
Examples here restricted to binary outcomes Wish to find sample size to definitively test for
treatment effect ≥ min
Minimum difference of clinical interest, min, is KNOWN
May be risk difference, relative risk, odds-ratio Do not care about SMALLER treatment differences
Desire to limit sample size to that needed if ≠ min
Control group event rate UNKNOWN Follow-up allows interim analysis to terminate
trial without ‘substantial’ enrollment over-running
![Page 3: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/3.jpg)
3
Case Study 1 CAPTURE Trial (Lancet, 1997(349):1429-35)
Unstable angina patients undergoing angioplasty 30-day cardiovascular event endpoint Control event rate may range from 10%-20% Wish 80% power to detect min = 1/3 reduction
(RR)
0.10 0.12 0.14 0.16 0.18 0.20
1000
1400
1800
2200
Control event rate
Sa
mp
le s
ize
fo
r 8
0%
po
we
r
![Page 4: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/4.jpg)
4
Case Study 2
Response rate study Control rate may range from 10% to 25% min = 10% absolute difference
0.10 0.15 0.20 0.25 0.30 0.35
600
700
800
900
1000
Control event rate
Sa
mp
le s
ize
fo
r 9
0%
po
we
r
![Page 5: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/5.jpg)
5
Can we adapt sample size? Gao, Ware and Mehta [2010] take a conditional power
approach to sample size re-estimation Presented by Cyrus Mehta at recent KOL lecture Would presumably plan for null hypothesis 0 > min
and adapt sample size up if interim treatment effect is “somewhat promising”
Information-based group sequential design
1. Estimate statistical information at analysis (blinded)
2. Do (interim or final) analysis based on proportion of final desired information (spending function approach)
3. If max information AND max sample size not reached– If desired information likely by next analysis, stop there– Otherwise, go to next interim– Go back to 1.
![Page 6: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/6.jpg)
6
Fair comparison?
The scenarios here are set up for information-based design to be preferred Other scenarios may point to a conditional power
approach Important to distinguish your situation to choose
the appropriate method! Scenarios where the information-based approach
works well are reasonably common Blinded approaches such as information-based
design are considered “well-understood’’ in the FDA draft guidance
![Page 7: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/7.jpg)
7
Information-based approach
Enroll patients continuously
Estimate current information
Analyze data
Estimate information @ next analysis
Go to final(may adapt) Go to next IA
Stop if done
Stop enrollment
![Page 8: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/8.jpg)
8
Example adaptation
200
325
200
200
275
200
334
525
200 200 300
Actual n
Observed
information
Planned n
A1
A2
A3
A4
A5
Target
Information is re-scaled
Adapted up to finish
![Page 9: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/9.jpg)
9
Estimating information: Notation
grouperimentalinproportion
sizesampleoveralln
_exp__
__
![Page 10: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/10.jpg)
10
Variance of (Note: =proportion in Arm E)
General formula
Absolute difference ( = pC – pE)
Relative risk ( = log(pE / pC ))
nVar /)ˆ( 2
/)1()1/()1(2EECC pppp
E
E
C
C
p
p
p
p )1(
)1(
)1(2
![Page 11: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/11.jpg)
11
Estimating variance and information
nraV /ˆ)ˆ(ˆ 2
Event rates estimated Assume overall blinded event rate Assume alternate hypothesis Use MLE estimate for treatment group
event rates (like M&N method) Use these event rates to estimate
Statistical information
21 ˆ/)ˆ(ˆ nraVI
![Page 12: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/12.jpg)
12
![Page 13: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/13.jpg)
13
![Page 14: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/14.jpg)
14
![Page 15: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/15.jpg)
15
CAPTURE information-based approach
Plan for maximum sample size of 2800 Analyze every 350 patients At each analysis
Compute proportion of planned information Analyze Adapt appropriately
![Page 16: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/16.jpg)
16
![Page 17: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/17.jpg)
17
![Page 18: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/18.jpg)
18
![Page 19: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/19.jpg)
19
Case Study 2
Response rate study Control rate may range from 10% to 25% min = 10% absolute difference
0.10 0.15 0.20 0.25 0.30 0.35
600
700
800
900
1000
Control event rate
Sa
mp
le s
ize
fo
r 9
0%
po
we
r
![Page 20: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/20.jpg)
20
Execution of the IA Strategy:Conditional power approach of Gao et al
Interim Analysis, calculate: • Rate Difference
Stop for futility
Diff<3.86%†
3.86%≤Diff<16.7%
Stop for efficacy
Diff≥16.7%‡
†Corresponding to a CP of 15%; ‡Corresponding to a P<0.0001.
Continue
Re-estimate Sample Size
CP<0.35 or CP> 0.85
0.35≤CP≤0.85
Compute Conditional Power
![Page 21: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/21.jpg)
21
Overall Power of the Study IA without SSR and IA with SSR
• Initial sample size is 289 in each case.• Maximum possible sample size is 578 (2 times of 289, cap of the SSR)
NSAIDS Response
Rate
DrugAResponse
Rate
gsDesign (Efficacy, Futility)
Adaptive (gsDesign+SSR)
E(N) †
/Group Power E(N) †
/Group Power
10% 20%
15% 25%
20% 30%
25% 35%
† E(N) = expected sample size, which is the average of the sample size for such a design. The actual sample size the study might end up with varies.
90.0%90.0% 92.4%92.4%278278
82.6%82.6%
78.2%78.2%
73.3%73.3%
86.8%86.8%
81.9%81.9%
78.0%78.0%
303303
273273
269269
266266
305305
306306
304304
![Page 22: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/22.jpg)
22
Information-based approach
![Page 23: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/23.jpg)
23
![Page 24: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/24.jpg)
24
Information-based approach
Maximum sample size of 1100 Plan analyses at 200, 400, 600, 800, 1100
Adapt assume targetmin = .10 Absolute response rate improvement
![Page 25: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/25.jpg)
25
![Page 26: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/26.jpg)
26
![Page 27: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/27.jpg)
27
Some comments
Computations performed using gsDesign R package Available at CRAN For CAPTURE example, 10k simulations were
performed for a large # of scenarios– Parallel computing was easily implemented using
Rmpi (free) or Parallel R (REvolution Computing) For smaller # of scenarios used for 2nd case study,
sequential processing on PC was fine My objective is to produce a vignette making this
method available
Technical issues Various issues such as over-running and
“reversing information time” need to be considered
![Page 28: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/28.jpg)
28
Objective: Fit-for-purpose sample-size adaptation
Examples here restricted to binary outcomes Wish to find sample size to definitively test for
treatment effect ≥ min
Minimum clinical difference of interest, min, is KNOWN
May be risk difference, relative risk, odds-ratio Do not care about SMALLER treatment differences
Desire to limit sample size to that needed if ≠ min
Control group event rate UNKNOWN Follow-up allows interim analysis to terminate
trial without ‘substantial’ enrollment over-running
![Page 29: 1 Keaven Anderson, Ph.D. Amy Ko, MPH Nancy Liu, Ph.D. Yevgen Tymofyeyev, Ph.D. Merck Research Laboratories June 9, 2010 Information-Based Sample Size Re-estimation.](https://reader036.fdocuments.in/reader036/viewer/2022062423/5697bf7d1a28abf838c84cdd/html5/thumbnails/29.jpg)
29
Summary
Information-based group sequential design for binary outcomes is Effective at adapting maximum sample size to
power for treatment effect ≥ min
Group sequential aspects terminate early for futility, large efficacy difference
Results demonstrated for absolute difference and relative risk examples
If you can posit a minimum effect size of interest, this may be an effective adaptation method